Fundraising Fox
/Companies
Sign in

MBQ Pharma

San Juan, US

Find your way into MBQ Pharma

Sign up to see every warm intro you have to MBQ Pharma

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the MBQ Pharma team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

MBQ Pharma develops precision therapeutics that target Rac and CDC42 GTPases for cancer, autoimmune, and fibrotic diseases, with a lead compound (MBQ-167) aimed at preventing and removing metastases. Its lead candidate is in a Phase 1 study, based on IP licensed from the University of Puerto Rico.

BiotechHealthtech

Founders & leadership

SD
SURANGANIE DHARMAWARDHANEChief Scientific Officer
CV
CORNELIS VLAARChief Development Officer
CACARLOS A DOMINGUEZ
CARLOS A DOMINGUEZChief Financial OfficerCarlos A Dominguez is a healthcare executive with over 27 years of pharmaceutical industry experience, including leadership roles at Biogen, Probiomed, MSD, Teva, and most recently as General Manager of Synthon Mexico, where he led commercial transformation and market development. He brings expertise in general management, business transformation, commercial strategy, and market access.
JFJOSE F RODRIGUEZ-ORENGO
JOSE F RODRIGUEZ-ORENGOChief Executive OfficerJosé F. Rodríguez-Orengó is Chief Business Officer at MBQ Pharma, which develops precision therapeutics targeting Rac and CDC42 GTPases for cancer and fibrotic diseases. He previously served as a biochemistry professor at the University of Puerto Rico School of Medicine and led clinical research operations at FDI Clinical Research.
FG
FEDERICO GOODSAIDChief Executive Officer
EH
ELIUD HERNANDEZChief Operating Officer

Board

AG
ARTURO GONZALEZBoard of Directors Member
HG
HUMBERTO GUZMANBoard of Directors Member

Reported raises · per SEC filings

Form D private placements

$4.2M disclosed across 5 rounds · 2018–2026

▶$1.5MraisedAug 2026 · 8 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • CARLOS A DOMINGUEZExecutive Officer
  • JOSE F RODRIGUEZ-ORENGOExecutive Officer
  • SURANGANIE DHARMAWARDHANEExecutive Officer, Director
  • FEDERICO GOODSAIDExecutive Officer, Director
  • CORNELIS VLAARExecutive Officer, Director
  • ELIUD HERNANDEZExecutive Officer
Amount sold
$1.5M
First sale
Jun 2018
Incorporated
Corporation, Puerto Rico
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$882KraisedAug 2026 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • CARLOS A DOMINGUEZExecutive Officer
  • JOSE F RODRIGUEZ-ORENGOExecutive Officer, Director
  • SURANGANIE DHARMAWARDHANEExecutive Officer
  • FEDERICO GOODSAIDExecutive Officer, Director
  • CORNELIS VLAARExecutive Officer, Director
  • ELIUD HERNANDEZExecutive Officer
  • ARTURO GONZALEZDirector
  • HUMBERTO GUZMANDirector
Offering amount
$882K
Amount sold
$882K
First sale
Feb 2021
Incorporated
Corporation, Puerto Rico
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$325KraisedAug 2026 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • CARLOS A DOMINGUEZExecutive Officer
  • JOSE F RODRIGUEZ-ORENGOExecutive Officer, Director
  • SURANGANIE DHARMAWARDHANEExecutive Officer
  • FEDERICO GOODSAIDExecutive Officer, Director
  • CORNELIS VLAARExecutive Officer, Director
  • ELIUD HERNANDEZExecutive Officer
  • ARTURO GONZALEZDirector
  • HUMBERTO GUZMANDirector
Offering amount
$325K
Amount sold
$325K
First sale
Mar 2022
Incorporated
Corporation, Puerto Rico
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$500KraisedAug 2026 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • CARLOS A DOMINGUEZExecutive Officer
  • JOSE F RODRIGUEZ-ORENGOExecutive Officer, Director
  • SURANGANIE DHARMAWARDHANEExecutive Officer
  • FEDERICO GOODSAIDDirector
  • CORNELIS VLAARDirector
  • ARTURO GONZALEZDirector
  • HUMBERTO GUZMANDirector
Offering amount
$500K
Amount sold
$500K
First sale
Aug 2023
Incorporated
Corporation, Puerto Rico
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$991KraisedAug 2026 · 8 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • CARLOS A DOMINGUEZExecutive Officer, Director
  • JOSE F RODRIGUEZ-ORENGOExecutive Officer, Director
  • SURANGANIE DHARMAWARDHANEExecutive Officer
  • ARTURO GONZALEZDirector
  • NEIL SANKARExecutive Officer
Amount sold
$991K
First sale
May 2026
Incorporated
Corporation, Puerto Rico
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

BioQ PharmaBioQ Pharma is a pharmaceutical company with expertise in biotech development and healthcare technology. The company appears to be focused on pharmaceutical innovation with a board of directors drawn from senior executives with extensive experience in biotech, medical devices, and pharma commercialization.
ResQ PharmaResQ Pharma is a pharmaceutical company developing LipidRescue (LRT), an investigational lipid-based drug therapy that is pending FDA approval. The company works on biologics development, regulatory affairs, and clinical research for its drug candidate.
STAQ PharmaSTAQ Pharma is an FDA-registered 503B outsourcing facility that compounds and supplies medications to hospitals and healthcare providers across the United States, aiming to address drug shortages. The company is owned and guided by several healthcare systems and focuses on safety, transparency, availability, and quality.

Companies working in the same space as MBQ Pharma.

Frequently asked questions

What does MBQ Pharma do?
MBQ Pharma develops precision therapeutics that target Rac and CDC42 GTPases for cancer, autoimmune, and fibrotic diseases, with a lead compound (MBQ-167) aimed at preventing and removing metastases. Its lead candidate is in a Phase 1 study, based on IP licensed from the University of Puerto Rico.
Who founded MBQ Pharma?
MBQ Pharma was founded by SURANGANIE DHARMAWARDHANE, CORNELIS VLAAR.
How much funding has MBQ Pharma raised?
MBQ Pharma has disclosed $4.2M raised across 5 rounds.
Where is MBQ Pharma headquartered?
MBQ Pharma is headquartered in San Juan, US.